Enrichment for this expression signature was tested in cancer, focusing on bladder cancer since these show mutations in TSC1 and/or TSC2 in about 15% of cases (Sjödahl et al., 2011; Pymar et al., 2008). Here, TSC1 is linked to urinary bladder cancer.